Cargando…

Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance

While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed that acquired resistance is accompanied by a gain in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellerby, Rebecca, Smith, Chris, Kyme, Sue, Gee, Julia, Günthert, Ursula, Green, Andy, Rakha, Emad, Barrett-Lee, Peter, Hiscox, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913094/
https://www.ncbi.nlm.nih.gov/pubmed/27379207
http://dx.doi.org/10.3389/fonc.2016.00145
_version_ 1782438364173041664
author Bellerby, Rebecca
Smith, Chris
Kyme, Sue
Gee, Julia
Günthert, Ursula
Green, Andy
Rakha, Emad
Barrett-Lee, Peter
Hiscox, Stephen
author_facet Bellerby, Rebecca
Smith, Chris
Kyme, Sue
Gee, Julia
Günthert, Ursula
Green, Andy
Rakha, Emad
Barrett-Lee, Peter
Hiscox, Stephen
author_sort Bellerby, Rebecca
collection PubMed
description While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed that acquired resistance is accompanied by a gain in cellular invasion and migration and also that CD44 family proteins are overexpressed in the resistant phenotype. Given the association of CD44 with tumor progression, we hypothesized that its overexpression may act to promote the aggressive behavior of endocrine-resistant breast cancers. Here, we have investigated further the role of two specific CD44 isoforms, CD44v3 and CD44v6, in the endocrine-resistant phenotype. Our data revealed that overexpression of CD44v6, but not CD44v3, in endocrine-sensitive MCF-7 cells resulted in a gain in EGFR signaling, enhanced their endogenous invasive capacity, and attenuated their response to endocrine treatment. Suppression of CD44v6 in endocrine-resistant cell models was associated with a reduction in their invasive capacity. Our data suggest that upregulation of CD44v6 in acquired resistant breast cancer may contribute to a gain in the aggressive phenotype of these cells and loss of endocrine response through transactivation of the EGFR pathway. Future therapeutic targeting of CD44v6 may prove to be an effective strategy alongside EGFR-targeted agents in delaying/preventing acquired resistance in breast cancer.
format Online
Article
Text
id pubmed-4913094
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49130942016-07-04 Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance Bellerby, Rebecca Smith, Chris Kyme, Sue Gee, Julia Günthert, Ursula Green, Andy Rakha, Emad Barrett-Lee, Peter Hiscox, Stephen Front Oncol Oncology While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed that acquired resistance is accompanied by a gain in cellular invasion and migration and also that CD44 family proteins are overexpressed in the resistant phenotype. Given the association of CD44 with tumor progression, we hypothesized that its overexpression may act to promote the aggressive behavior of endocrine-resistant breast cancers. Here, we have investigated further the role of two specific CD44 isoforms, CD44v3 and CD44v6, in the endocrine-resistant phenotype. Our data revealed that overexpression of CD44v6, but not CD44v3, in endocrine-sensitive MCF-7 cells resulted in a gain in EGFR signaling, enhanced their endogenous invasive capacity, and attenuated their response to endocrine treatment. Suppression of CD44v6 in endocrine-resistant cell models was associated with a reduction in their invasive capacity. Our data suggest that upregulation of CD44v6 in acquired resistant breast cancer may contribute to a gain in the aggressive phenotype of these cells and loss of endocrine response through transactivation of the EGFR pathway. Future therapeutic targeting of CD44v6 may prove to be an effective strategy alongside EGFR-targeted agents in delaying/preventing acquired resistance in breast cancer. Frontiers Media S.A. 2016-06-20 /pmc/articles/PMC4913094/ /pubmed/27379207 http://dx.doi.org/10.3389/fonc.2016.00145 Text en Copyright © 2016 Bellerby, Smith, Kyme, Gee, Günthert, Green, Rakha, Barrett-Lee and Hiscox. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bellerby, Rebecca
Smith, Chris
Kyme, Sue
Gee, Julia
Günthert, Ursula
Green, Andy
Rakha, Emad
Barrett-Lee, Peter
Hiscox, Stephen
Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title_full Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title_fullStr Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title_full_unstemmed Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title_short Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
title_sort overexpression of specific cd44 isoforms is associated with aggressive cell features in acquired endocrine resistance
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913094/
https://www.ncbi.nlm.nih.gov/pubmed/27379207
http://dx.doi.org/10.3389/fonc.2016.00145
work_keys_str_mv AT bellerbyrebecca overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT smithchris overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT kymesue overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT geejulia overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT gunthertursula overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT greenandy overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT rakhaemad overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT barrettleepeter overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance
AT hiscoxstephen overexpressionofspecificcd44isoformsisassociatedwithaggressivecellfeaturesinacquiredendocrineresistance